Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Biological Activity of a New Prolonged Release Formulation of Octreotide Acetate, C2l-OCT-01 PR, Administered Intra Muscularly Every 4, 5 or 6 Weeks in Acromegalic Patients

NCT00642421 is registered in ClinicalTrials.gov with Ambrilia Biopharma, Inc. as lead sponsor.

NCT NCT00642421
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00642421 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Biological Activity of a New Prolonged Release Formulation of Octreotide Acetate, C2l-OCT-01 PR, Administered Intra Muscularly Every 4, 5 or 6 Weeks in Acromegalic Patients
Lead sponsor
Ambrilia Biopharma, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
February 29, 2008
Completion date
August 31, 2009
Enrollment
40 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

acromegaly